Peptide-based self-assembled nanostructures offer great promise for targeted drug delivery due to their intrinsic biocompatibility, biodegradability, and structural tunability. However, their limited optical properties and lack of functional sites for selective targeting restrict their use in theranostics. Here, we report a fluorophore-integrated, pH-responsive dipeptide nanocarrier engineered from phenylalanine-tryptophan (F-W) conjugated with 4-chloro-7-nitrobenzofurazan (NBD) as a fluorescent probe and vitamin B6 (VitB6) as a pH-sensitive unit. The resulting vitamin B6-modified nanoparticles (PS-Dox) exhibited charge reversal from negative to positive under mildly acidic conditions (pH 5.0), promoting doxorubicin (Dox) release, endosomal escape, and nuclear localization. PS-Dox demonstrated enhanced cytotoxicity, DNA damage, and apoptosis induction in multiple cancer cell lines, while showing negligible toxicity toward non-malignant cardiomyocytes (AC-16 and H9C2). In vivo biodistribution and pharmacokinetic studies revealed increased tumour accumulation and superior tumour growth inhibition compared with Dox. Importantly, PS-mediated encapsulation effectively mitigated Dox-associated cardiotoxicity, a major limitation of conventional chemotherapy. Overall, this study establishes a vitamin B6-mediated, charge-reversible peptide nanocarrier as a biocompatible and efficient platform for targeted anticancer drug delivery, combining tumour-specific therapeutic efficacy with improved cardiac safety.
Nayak et al. (Sat,) studied this question.